BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bailly C, Thuru X, Quesnel B. Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases. Cancers (Basel) 2021;13:3034. [PMID: 34204509 DOI: 10.3390/cancers13123034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Kuchroo JR, Hafler DA, Sharpe AH, Lucca LE. The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity. Sci Immunol 2021;6:eabf4034. [PMID: 34739340 DOI: 10.1126/sciimmunol.abf4034] [Reference Citation Analysis]
2 Li B, Pu W, Weng L, Lyu P, Xu H, Zhang W, Ge L, Kwok HF, Wu Q. Aptamer‐functionalized Ti 3 C 2 ‐MXene Nanosheets with One‐step Potentiometric Detection of Programmed Death‐ligand 1. Electroanalysis 2022;34:2-7. [DOI: 10.1002/elan.202100438] [Reference Citation Analysis]
3 Xing Y, Liu J, Luo J, Ming T, Yang G, Sun S, Xu S, Li X, He E, Kong F, Yan S, Yang Y, Cai X. A Dual-Channel Intelligent Point-of-Care Testing System for Soluble Programmed Death-1 and Programmed Death-Ligand 1 Detection Based on Folding Paper-Based Immunosensors. ACS Sens . [DOI: 10.1021/acssensors.1c02486] [Reference Citation Analysis]
4 Adorisio S, Cannarile L, Delfino DV, Ayroldi E. Glucocorticoid and PD-1 Cross-Talk: Does the Immune System Become Confused? Cells 2021;10:2333. [PMID: 34571982 DOI: 10.3390/cells10092333] [Reference Citation Analysis]
5 Karaboué A, Collon T, Pavese I, Bodiguel V, Cucherousset J, Zakine E, Innominato PF, Bouchahda M, Adam R, Lévi F. Time-Dependent Efficacy of Checkpoint Inhibitor Nivolumab: Results from a Pilot Study in Patients with Metastatic Non-Small-Cell Lung Cancer. Cancers 2022;14:896. [DOI: 10.3390/cancers14040896] [Reference Citation Analysis]
6 Kummer MP, Ising C, Kummer C, Sarlus H, Griep A, Vieira-Saecker A, Schwartz S, Halle A, Brückner M, Händler K, Schultze JL, Beyer M, Latz E, Heneka MT. Microglial PD-1 stimulation by astrocytic PD-L1 suppresses neuroinflammation and Alzheimer's disease pathology. EMBO J 2021;40:e108662. [PMID: 34825707 DOI: 10.15252/embj.2021108662] [Reference Citation Analysis]
7 Erol A. Importance of Efferocytosis in COVID-19 Mortality. IDR 2022;Volume 15:995-1007. [DOI: 10.2147/idr.s348639] [Reference Citation Analysis]
8 Wang T, Denman D, Bacot SM, Feldman GM. Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy. Biomedicines 2022;10:1181. [DOI: 10.3390/biomedicines10051181] [Reference Citation Analysis]
9 Turiello R, Capone M, Morretta E, Monti MC, Madonna G, Azzaro R, Del Gaudio P, Simeone E, Sorrentino A, Ascierto PA, Morello S. Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents. J Immunother Cancer 2022;10:e004043. [PMID: 35273100 DOI: 10.1136/jitc-2021-004043] [Reference Citation Analysis]
10 Entezari M, Sadrkhanloo M, Rashidi M, Asnaf SE, Taheriazam A, Hashemi M, Ashrafizadeh M, Zarrabi A, Rabiee N, Hushmandi K, Mirzaei S, Sethi G. Non-coding RNAs and macrophage interaction in tumor progression. Crit Rev Oncol Hematol 2022;:103680. [PMID: 35405273 DOI: 10.1016/j.critrevonc.2022.103680] [Reference Citation Analysis]
11 Lu F, Dong Y, Li Q, Wang M, Tang M. The Change of Soluble Programmed Death Ligand 1 (sPD-L1) in Plasma of Small Cell Lung Cancer and Its Clinical Significance. Computational and Mathematical Methods in Medicine 2022;2022:1-6. [DOI: 10.1155/2022/8375349] [Reference Citation Analysis]
12 Niu M, Liu Y, Yi M, Jiao D, Wu K. Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer. Front Immunol 2022;13:827921. [DOI: 10.3389/fimmu.2022.827921] [Reference Citation Analysis]